A randomised Phase III trial of Glufosfamide (cas 132682-98-5) compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine☆
-
Add time:08/24/2019 Source:sciencedirect.com
PurposeThere are currently no approved therapies for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine. This Phase III trial evaluated the efficacy and safety of Glufosfamide (cas 132682-98-5) as compared with best supportive care (BSC) in this patient population.
We also recommend Trading Suppliers and Manufacturers of Glufosfamide (cas 132682-98-5). Pls Click Website Link as below: cas 132682-98-5 suppliers
Prev:Stability of Glufosfamide (cas 132682-98-5) in phosphate buffers and in biological samples
Next:A Novel Alkylating Agent, Glufosfamide (cas 132682-98-5), Enhances the Activity of Gemcitabine In Vitro, In Vivo) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Glufosfamide (cas 132682-98-5) administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group☆08/28/2019
- Glufosfamide (cas 132682-98-5) administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer: a phase II trial of the EORTC-New Drug Development Group☆08/27/2019
- Molecular and Cellular PharmacologyPossible contribution of β-glucosidase and caspases in the cytotoxicity of Glufosfamide (cas 132682-98-5) in colon cancer cells08/26/2019
- A Novel Alkylating Agent, Glufosfamide (cas 132682-98-5), Enhances the Activity of Gemcitabine In Vitro, In Vivo08/25/2019
- Stability of Glufosfamide (cas 132682-98-5) in phosphate buffers and in biological samples08/23/2019
